TUCSON, AZ--(Marketwired - Apr 22, 2015) - CDEX Inc. (OTCQB: CDEX), a pioneering developer, manufacturer and distributor of patented, real-time chemical detection and validation technologies for the healthcare and security markets, today announced that the United States Patent and Trademark Office has granted the Company U.S. Patent 9,013,686 B2, relating to the methods for identification and determination of unknown substances using Enhanced Photoemission Spectroscopy.

Jeffrey Brumfield, CDEX Chairman and CEO, stated, "This newly issued patent demonstrates our continuous efforts to remain on the forefront of innovation within the industry. Moreover, it validates the ValiMed™ System's capabilities to identify specific molecules in a substance and determine their concentration in both single and multiple-substance mixtures. As CDEX strengthens its efforts to support patient safety and fight against narcotic diversion, our technology will continue to evolve to meet the next new challenge."

About CDEX Inc.

Headquartered in Tucson, Arizona, CDEX is engaged in pioneering technological advancements in the field of chemical and medication detection and validation for the healthcare and security markets. The Company's proprietary solutions are based on its patented Enhanced Photoemission Spectroscopy technology for substance verification, authentication and identification; and include the ValiMed™ Medication Validation System product line marketed to healthcare markets worldwide for use in combatting diversion of controlled substances and narcotics, as well as compounded liquid pharmaceuticals to help ensure patient safety, and the ID2™ product line marketed to the global security market for use in detecting illegal or illicit drugs in difficult-to-monitor, critical environments. For more information, please visit www.cdex-inc.com.

Forward-Looking Statements

This news release may contain forward-looking statements. Forward-looking statements are indicated by words such as "expects," "intends," "anticipates," "believes," "forecasts," "plans" and similar expressions. These forward looking statements are based on our current expectations and actual results could differ materially. Our ability to achieve the results anticipated in such forward-looking statements is subject to risks and uncertainties, including, without limitation, our ability to successfully centralize and consolidate various support functions, operating results, market acceptance of our solutions, strong brand recognition and other risks detailed from time to time in our reports filed with the Securities and Exchange Commission. These forward-looking statements are made in accordance with "safe harbor" provided by the Private Securities Litigation Reform Act of 1995 and no assurance can be given that the future results that are the subject of such forward-looking statements will be achieved. The Company undertakes no obligation to publicly update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.